New 4-Drug cocktail aims to crush myeloma early
NCT ID NCT01559935
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 study tested a sequence of four drugs—carfilzomib, clarithromycin, lenalidomide, and dexamethasone—in 74 people newly diagnosed with multiple myeloma. The goal was to see how safe and effective this combination is at controlling the disease. Participants first received carfilzomib with dexamethasone, followed by the other three drugs, then lenalidomide alone. The study measured how many patients achieved a deep response and how long they stayed free of disease progression.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- carfilzomib, clarithromycin, lenalidomide, and dexamethasone
- What this could lead to
- If successful, this combination could offer a more effective initial treatment for multiple myeloma, potentially leading to deeper remissions and longer disease control.
- What could go wrong
- This is a phase 2 trial with only 74 participants, so results are preliminary. The drug combination may cause significant side effects, and not all patients may respond. Long-term benefits are not yet proven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Weill Cornell Medical College
New York, New York, 10021, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can a Triple-Action antibody deepen remissions in myeloma?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?
- A guided path back to work after blood cancer: a trial tests the impact